Tyrosine kinase inhibitor dose reduction during the management of accelerated phase chronic myeloid leukemia

Ortí G, García-Gutiérrez V, Bautista G, Ferrer-Marín F, Vallansot R, Xicoy B, Sánchez À, Simon I, Triguero A, Sierra M, Casado LF; Grupo Español de Leucemia Mieloide Crónica (GELMC).